Trade Karyopharm - KPTI CFD
Add to favourite- Summary
- Historical Data
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 1.04 |
Open | 1 |
1-Year Change | -73.12% |
Day's Range | 1 - 1.05 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 25, 2024 | 1.04 | 0.00 | 0.00% | 1.04 | 1.07 | 1.01 |
Apr 24, 2024 | 1.07 | 0.00 | 0.00% | 1.07 | 1.12 | 1.03 |
Apr 23, 2024 | 1.06 | -0.03 | -2.75% | 1.09 | 1.14 | 1.06 |
Apr 22, 2024 | 1.10 | -0.04 | -3.51% | 1.14 | 1.18 | 1.10 |
Apr 19, 2024 | 1.14 | -0.10 | -8.06% | 1.24 | 1.28 | 1.11 |
Apr 18, 2024 | 1.25 | -0.13 | -9.42% | 1.38 | 1.38 | 1.20 |
Apr 17, 2024 | 1.35 | 0.23 | 20.54% | 1.12 | 1.35 | 1.11 |
Apr 16, 2024 | 1.07 | -0.02 | -1.83% | 1.09 | 1.17 | 1.02 |
Apr 15, 2024 | 1.13 | -0.06 | -5.04% | 1.19 | 1.20 | 1.12 |
Apr 12, 2024 | 1.19 | -0.09 | -7.03% | 1.28 | 1.32 | 1.15 |
Apr 11, 2024 | 1.31 | 0.06 | 4.80% | 1.25 | 1.31 | 1.24 |
Apr 10, 2024 | 1.24 | -0.05 | -3.88% | 1.29 | 1.30 | 1.23 |
Apr 9, 2024 | 1.32 | 0.01 | 0.76% | 1.31 | 1.38 | 1.29 |
Apr 8, 2024 | 1.32 | -0.02 | -1.49% | 1.34 | 1.35 | 1.27 |
Apr 5, 2024 | 1.33 | 0.06 | 4.72% | 1.27 | 1.39 | 1.26 |
Apr 4, 2024 | 1.31 | 0.05 | 3.97% | 1.26 | 1.41 | 1.23 |
Apr 3, 2024 | 1.26 | -0.10 | -7.35% | 1.36 | 1.36 | 1.26 |
Apr 2, 2024 | 1.37 | -0.14 | -9.27% | 1.51 | 1.52 | 1.36 |
Apr 1, 2024 | 1.56 | 0.08 | 5.41% | 1.48 | 1.62 | 1.43 |
Mar 28, 2024 | 1.48 | 0.06 | 4.23% | 1.42 | 1.57 | 1.41 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Karyopharm Company profile
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Karyopharm Therapeutics Inc revenues increased 94% to $209.8M. Net loss decreased 37% to $124.1M. Revenues reflect License and other revenue increase from $31.9M to $111.4M, Product revenue, net increase of 29% to $98.4M. Lower net loss reflects Interest expense decrease of 4% to $26M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.72 to -$1.65.
Equity composition
Common Stock $0.0001 Par, 11/13, 100M auth., 28,729,593 issd. Insiders own approx. 76.33%
Industry: | Bio Therapeutic Drugs |
85 Wells Ave
NEWTON CENTER
MASSACHUSETTS 02459-3298
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com